What Globus Medical (GMED)'s Upgraded Earnings Outlook and Rising ROIC Concerns Mean For Shareholders

• In early June 2026, Globus Medical reported a strong first quarter with 27% overall revenue growth, record earnings, and reaffirmed full‑year revenue guidance while lifting its non‑GAAP EPS outlook, supported by broad-based strength in its spine and enabling technologies businesses and ongoing integration of the Nevro acquisition.
• Alongside this momentum, the company’s declining return on invested capital has raised questions about how efficiently it can sustain profitable growth even as it expands globally and rolls out new products.
• With this backdrop of upgraded earnings guidance, we’ll examine how the latest results and outlook revisions may reshape Globus Medical’s investment narrative.

Find 46 companies with promising cash flow potential yet trading below their fair value.

Globus Medical Investment Narrative Recap

To own Globus Medical, you have to believe that its spine and enabling technologies platform can convert strong procedure demand and new products into durable, profitable growth. The latest quarter reinforced that story by pairing 27% revenue growth with higher earnings guidance, which supports the near term catalyst around continued adoption of robotics and navigation. The biggest watchpoint, in my view, remains execution on acquisitions like Nevro and NuVasive, where integration missteps or weaker returns on capital could still

Among the recent updates, the reaffirmed 2026 revenue outlook of US$3.18 billion to US$3.33 billion and higher non GAAP EPS guidance to US$4.70 to US$4.80 stand out. That combination of faster earnings and steady top line targets directly connects to the key catalyst of improving margins from manufacturing efficiencies, cost control and acquired assets, while also putting more focus on whether integration and ROIC trends can keep pace with the stronger profit outlook.

Read the full narrative on Globus Medical (it's free!)

Globus Medical's narrative projects $3.7 billion revenue and $649.0 million earnings by 2029. This requires 5.8% yearly revenue growth and about a $62 million earnings increase from $586.7 million today.

Uncover how Globus Medical's forecasts yield a $110.00 fair value, a 37% upside to its current price.

Exploring Other Perspectives

Yet some of the lowest analysts were assuming only about US$3.4 billion of revenue and US$462 million of earnings by 2028, which shows how cautious views on integration risks and margin progress can differ sharply from the more upbeat read of today’s strong results and may shift again as new data comes in.

Explore 5 other fair value estimates on Globus Medical - why the stock might be worth as much as 98% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Globus Medical research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Globus Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globus Medical's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com